01—Abstract
Summary
Summary of the 8-K filed February 15, 2024. Cited figures are marked; the original filing is the authoritative source.
West Pharmaceutical Services, Inc. (NYSE: WST) reported fourth-quarter 2023 net sales of $732.0 milliona, up 3.3%, with organic net sales growth of 1.4%.
Full-year 2023 net sales were $2.950 billionb, up 2.2%, with organic net sales growth of 1.6%. Reported-diluted EPS was $1.83 for the quarter (up 34.6%) and $7.88 for the year (up 1.9%). Adjusted-diluted EPS was $1.83 for the quarter (up 3.4%) and $8.08 for the full year (down 5.8%), per the non-U.S. GAAP measures in the release.
Management introduced full-year 2024 guidance of net sales of $3.000 billion to $3.025 billionc, with organic net sales growth of approximately 2% to 3%, and adjusted-diluted EPS of $7.50 to $7.75. CEO Eric M. Green said 2024 organic sales growth is expected to moderate, with headwinds most pronounced in the first quarter and a stronger second half expected, supported by the February order book for the second half of the year.
Full-year 2024 capital spending is expected to be $350 milliond, including capacity expansions at existing high-value product and contract manufacturing facilities. Full-year 2023 operating cash flow was $776.5 million and capital expenditures were $362.0 million, leaving free cash flow of $414.5 million.
The company repurchased 1,265,661 shares for $438.3 million during 2023. The Proprietary Products segment had full-year net sales of $2.397 billion, and the Contract-Manufactured Products segment had $552.5 million, up 15.0%.
02—Key points
Key Highlights
- Q4 2023 net sales of $732.0 million, up 3.3%; organic net sales growth of 1.4%.
- FY 2023 net sales of $2.950 billion, up 2.2%; organic net sales growth of 1.6%.
- FY 2023 adjusted-diluted EPS of $8.08, down 5.8%; reported-diluted EPS of $7.88, up 1.9%.
- FY 2024 guidance: net sales of $3.000 billion to $3.025 billion and adjusted-diluted EPS of $7.50 to $7.75.
- Management expects moderated organic sales growth in 2024 (about 2% to 3%), with headwinds concentrated in Q1 and a stronger second half.
- Contract-Manufactured Products full-year net sales grew 15.0% to $552.5 million, with organic growth of 13.8%.
- Free cash flow of $414.5 million in 2023 on operating cash flow of $776.5 million and capital expenditures of $362.0 million; $438.3 million spent on share repurchases.
03—Questions
Frequently Asked Questions
How did West Pharmaceutical perform in the fourth quarter of 2023?
Net sales were $732.0 million, up 3.3%, with organic net sales growth of 1.4%. Reported-diluted EPS was $1.83, up 34.6%, and adjusted-diluted EPS was $1.83, up 3.4%.
What is the company's full-year 2024 outlook?
Management guided to net sales of $3.000 billion to $3.025 billion, organic net sales growth of approximately 2% to 3%, and adjusted-diluted EPS of $7.50 to $7.75. The guidance includes an estimated $8 million net sales headwind and an approximately $0.02 EPS headwind from current foreign exchange rates.
Why does management expect slower growth in early 2024?
Management expects moderated organic sales growth as it manages inventory timing, especially with its largest customers. Headwinds are expected to be more pronounced in the first quarter and less impactful afterward, with stronger organic growth expected in the second half.
What drove segment performance in 2023?
The Proprietary Products segment had full-year net sales of $2.397 billion, down 0.4%, with organic net sales down 0.8%. High-value product components and devices were about 74% of segment sales. The Contract-Manufactured Products segment grew 15.0% to $552.5 million, led by medical device and diagnostic products.
How much capital did the company return to shareholders and invest in 2023?
The company repurchased 1,265,661 shares for $438.3 million, an average of $346.34 per share. Capital expenditures were $362.0 million, and 2024 capital spending is expected to be $350 million.
04—Continue